A combination of sorafenib with vorinostat induced a ceramide-dependent promotion of cell death associated with CD95 signaling in various tumor cell lines [20] and an elevation of dihydroceramides was observed upstream of CD95 activation [19]. Here, FAS is linked to neoplasm.